Global Vaginal Yeast Infections Drug Market Growth 2026-2032
The global Vaginal Yeast Infections Drug market size is predicted to grow from US$ 1002 million in 2025 to US$ 1492 million in 2032; it is expected to grow at a CAGR of 5.9% from 2026 to 2032.
Vaginal yeast infection drugs are antifungal medicines and dosage-form systems used to treat vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), spanning intravaginal topicals (creams, suppositories, tablets) and oral agents. Legacy therapy is largely anchored by azoles for episodic relief and, in recurrence, structured induction-plus-maintenance regimens. For non-albicans Candida or suspected resistance, guidance emphasizes culture/speciation to align drug choice and duration. In 2025, global Vaginal yeast infections drugs production reached approximately 227.56 million units and price is about 4.5 USD/Unit.The average gross profit margin of this product is 35%.
The category is propelled by a dual engine: high-frequency OTC demand for rapid relief and prescription-layered stratification for recurrent disease. While episodic VVC is often managed with topical azoles and legacy oral options, RVVC creates a structurally different need for durable control. FDA labeling has clarified two innovation tracks: ibrexafungerp (BREXAFEMME) is indicated for VVC treatment and for reducing RVVC incidence, and oteseconazole (VIVJOA) is indicated to reduce RVVC incidence with defined population limitations—expanding portfolio space from one-off therapy to long-horizon management.
The main friction is “insufficient diagnosis + heterogeneous patients.” Under-testing fuels mis-treatment and recurrence cycles, especially in non-albicans Candida (e.g., C. glabrata) or reduced fluconazole response. ACOG and CDC guidance emphasizes culture/speciation for recurrent or refractory cases and regimen selection aligned with organism and response. Newer agents often come with tighter population boundaries and safety constraints (e.g., VIVJOA’s “not of reproductive potential” limitation), alongside payer scrutiny of long-term value, requiring robust real-world evidence and pathway discipline to reduce uncertainty.
Demand is shifting from symptom relief to recurrence-risk governance. Providers increasingly segment care: convenience-driven short courses for uncomplicated cases, and traceable induction-to-maintenance pathways for RVVC. For non-albicans infection or poor response, culture/speciation and regimen switching are embedded into workflow. Meanwhile, telehealth, pharmacy access, and women’s health platforms are building a “self-triage ? initial treatment ? referral/return-visit routing” loop, pushing branded therapies to differentiate on recurrence control, adherence support, and long-term satisfaction rather than commodity positioning.
Upstream advantage is defined by stable delivery across API, formulation engineering, and compliance systems. Legacy azoles depend on mature synthesis routes, impurity and polymorph control, and vaginal dosage-form design that balances efficacy with tolerability through excipient/base selection and local tissue compatibility. Innovative oral agents raise the bar on complex intermediates, batch consistency, and regulatory documentation. Given the long-horizon nature of RVVC management, suppliers must also industrialize packaging compatibility, stability, traceability, and pharmacovigilance-ready quality systems to support scalable prescription-market adoption.
LP Information, Inc. (LPI) ' newest research report, the “Vaginal Yeast Infections Drug Industry Forecast” looks at past sales and reviews total world Vaginal Yeast Infections Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Vaginal Yeast Infections Drug sales for 2026 through 2032. With Vaginal Yeast Infections Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaginal Yeast Infections Drug industry.
This Insight Report provides a comprehensive analysis of the global Vaginal Yeast Infections Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaginal Yeast Infections Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vaginal Yeast Infections Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaginal Yeast Infections Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaginal Yeast Infections Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaginal Yeast Infections Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Vaginal Yeast Infections Drug market?
What factors are driving Vaginal Yeast Infections Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaginal Yeast Infections Drug market opportunities vary by end market size?
How does Vaginal Yeast Infections Drug break out by Type, by Application?
Vaginal yeast infection drugs are antifungal medicines and dosage-form systems used to treat vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), spanning intravaginal topicals (creams, suppositories, tablets) and oral agents. Legacy therapy is largely anchored by azoles for episodic relief and, in recurrence, structured induction-plus-maintenance regimens. For non-albicans Candida or suspected resistance, guidance emphasizes culture/speciation to align drug choice and duration. In 2025, global Vaginal yeast infections drugs production reached approximately 227.56 million units and price is about 4.5 USD/Unit.The average gross profit margin of this product is 35%.
The category is propelled by a dual engine: high-frequency OTC demand for rapid relief and prescription-layered stratification for recurrent disease. While episodic VVC is often managed with topical azoles and legacy oral options, RVVC creates a structurally different need for durable control. FDA labeling has clarified two innovation tracks: ibrexafungerp (BREXAFEMME) is indicated for VVC treatment and for reducing RVVC incidence, and oteseconazole (VIVJOA) is indicated to reduce RVVC incidence with defined population limitations—expanding portfolio space from one-off therapy to long-horizon management.
The main friction is “insufficient diagnosis + heterogeneous patients.” Under-testing fuels mis-treatment and recurrence cycles, especially in non-albicans Candida (e.g., C. glabrata) or reduced fluconazole response. ACOG and CDC guidance emphasizes culture/speciation for recurrent or refractory cases and regimen selection aligned with organism and response. Newer agents often come with tighter population boundaries and safety constraints (e.g., VIVJOA’s “not of reproductive potential” limitation), alongside payer scrutiny of long-term value, requiring robust real-world evidence and pathway discipline to reduce uncertainty.
Demand is shifting from symptom relief to recurrence-risk governance. Providers increasingly segment care: convenience-driven short courses for uncomplicated cases, and traceable induction-to-maintenance pathways for RVVC. For non-albicans infection or poor response, culture/speciation and regimen switching are embedded into workflow. Meanwhile, telehealth, pharmacy access, and women’s health platforms are building a “self-triage ? initial treatment ? referral/return-visit routing” loop, pushing branded therapies to differentiate on recurrence control, adherence support, and long-term satisfaction rather than commodity positioning.
Upstream advantage is defined by stable delivery across API, formulation engineering, and compliance systems. Legacy azoles depend on mature synthesis routes, impurity and polymorph control, and vaginal dosage-form design that balances efficacy with tolerability through excipient/base selection and local tissue compatibility. Innovative oral agents raise the bar on complex intermediates, batch consistency, and regulatory documentation. Given the long-horizon nature of RVVC management, suppliers must also industrialize packaging compatibility, stability, traceability, and pharmacovigilance-ready quality systems to support scalable prescription-market adoption.
LP Information, Inc. (LPI) ' newest research report, the “Vaginal Yeast Infections Drug Industry Forecast” looks at past sales and reviews total world Vaginal Yeast Infections Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Vaginal Yeast Infections Drug sales for 2026 through 2032. With Vaginal Yeast Infections Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaginal Yeast Infections Drug industry.
This Insight Report provides a comprehensive analysis of the global Vaginal Yeast Infections Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaginal Yeast Infections Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vaginal Yeast Infections Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaginal Yeast Infections Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaginal Yeast Infections Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaginal Yeast Infections Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Topical Drugs
- Oral Drugs
- Uncomplicated VVC
- Complicated VVC
- Other
- Azoles
- Polyenes
- Novel Oral Antifungals
- Other
- Hospital Pharmacies
- Retail Pharmacies
- Online
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Bayer
- Sanofi
- Teva Pharmaceuticals
- Sandoz
- Prestige Consumer Healthcare
- Lupin Pharmaceuticals
- Bausch Health
- Globela Pharma
- Padagis
- Galderma
- Perrigo
- Johnson & Johnson
- Sinopharm Group
- Tongfang Pharmaceutical
- Lukang Pharmaceutical
- Kelun Pharmaceutical
- Shijiazhuang Pharmaceutical Group
- Livzon Pharmaceutical
- Wuhan Haite Biopharmaceutical
What is the 10-year outlook for the global Vaginal Yeast Infections Drug market?
What factors are driving Vaginal Yeast Infections Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaginal Yeast Infections Drug market opportunities vary by end market size?
How does Vaginal Yeast Infections Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaginal Yeast Infections Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Vaginal Yeast Infections Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Vaginal Yeast Infections Drug by Country/Region, 2021, 2025 & 2032
2.2 Vaginal Yeast Infections Drug Segment by Type
2.2.1 Topical Drugs
2.2.2 Oral Drugs
2.2.3 Vaginal Yeast Infections Drug Sales by Type
2.2.3.1 Global Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
2.2.3.2 Global Vaginal Yeast Infections Drug Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Vaginal Yeast Infections Drug Sale Price by Type (2021-2026)
2.3 Vaginal Yeast Infections Drug Segment by Disease Type
2.3.1 Uncomplicated VVC
2.3.2 Complicated VVC
2.3.3 Other
2.3.4 Vaginal Yeast Infections Drug Sales by Disease Type
2.3.4.1 Global Vaginal Yeast Infections Drug Sales Market Share by Disease Type (2021-2026)
2.3.4.2 Global Vaginal Yeast Infections Drug Revenue and Market Share by Disease Type (2021-2026)
2.3.4.3 Global Vaginal Yeast Infections Drug Sale Price by Disease Type (2021-2026)
2.4 Vaginal Yeast Infections Drug Segment by Drug Class
2.4.1 Azoles
2.4.2 Polyenes
2.4.3 Novel Oral Antifungals
2.4.4 Other
2.4.5 Vaginal Yeast Infections Drug Sales by Drug Class
2.4.5.1 Global Vaginal Yeast Infections Drug Sales Market Share by Drug Class (2021-2026)
2.4.5.2 Global Vaginal Yeast Infections Drug Revenue and Market Share by Drug Class (2021-2026)
2.4.5.3 Global Vaginal Yeast Infections Drug Sale Price by Drug Class (2021-2026)
2.5 Vaginal Yeast Infections Drug Segment by Application
2.5.1 Hospital Pharmacies
2.5.2 Retail Pharmacies
2.5.3 Online
2.5.4 Vaginal Yeast Infections Drug Sales by Application
2.5.4.1 Global Vaginal Yeast Infections Drug Sale Market Share by Application (2021-2026)
2.5.4.2 Global Vaginal Yeast Infections Drug Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Vaginal Yeast Infections Drug Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Vaginal Yeast Infections Drug Breakdown Data by Company
3.1.1 Global Vaginal Yeast Infections Drug Annual Sales by Company (2021-2026)
3.1.2 Global Vaginal Yeast Infections Drug Sales Market Share by Company (2021-2026)
3.2 Global Vaginal Yeast Infections Drug Annual Revenue by Company (2021-2026)
3.2.1 Global Vaginal Yeast Infections Drug Revenue by Company (2021-2026)
3.2.2 Global Vaginal Yeast Infections Drug Revenue Market Share by Company (2021-2026)
3.3 Global Vaginal Yeast Infections Drug Sale Price by Company
3.4 Key Manufacturers Vaginal Yeast Infections Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaginal Yeast Infections Drug Product Location Distribution
3.4.2 Players Vaginal Yeast Infections Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VAGINAL YEAST INFECTIONS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Vaginal Yeast Infections Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global Vaginal Yeast Infections Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Vaginal Yeast Infections Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Vaginal Yeast Infections Drug Market Size by Country/Region (2021-2026)
4.2.1 Global Vaginal Yeast Infections Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global Vaginal Yeast Infections Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Vaginal Yeast Infections Drug Sales Growth
4.4 APAC Vaginal Yeast Infections Drug Sales Growth
4.5 Europe Vaginal Yeast Infections Drug Sales Growth
4.6 Middle East & Africa Vaginal Yeast Infections Drug Sales Growth
5 AMERICAS
5.1 Americas Vaginal Yeast Infections Drug Sales by Country
5.1.1 Americas Vaginal Yeast Infections Drug Sales by Country (2021-2026)
5.1.2 Americas Vaginal Yeast Infections Drug Revenue by Country (2021-2026)
5.2 Americas Vaginal Yeast Infections Drug Sales by Type (2021-2026)
5.3 Americas Vaginal Yeast Infections Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaginal Yeast Infections Drug Sales by Region
6.1.1 APAC Vaginal Yeast Infections Drug Sales by Region (2021-2026)
6.1.2 APAC Vaginal Yeast Infections Drug Revenue by Region (2021-2026)
6.2 APAC Vaginal Yeast Infections Drug Sales by Type (2021-2026)
6.3 APAC Vaginal Yeast Infections Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaginal Yeast Infections Drug by Country
7.1.1 Europe Vaginal Yeast Infections Drug Sales by Country (2021-2026)
7.1.2 Europe Vaginal Yeast Infections Drug Revenue by Country (2021-2026)
7.2 Europe Vaginal Yeast Infections Drug Sales by Type (2021-2026)
7.3 Europe Vaginal Yeast Infections Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaginal Yeast Infections Drug by Country
8.1.1 Middle East & Africa Vaginal Yeast Infections Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa Vaginal Yeast Infections Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa Vaginal Yeast Infections Drug Sales by Type (2021-2026)
8.3 Middle East & Africa Vaginal Yeast Infections Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaginal Yeast Infections Drug
10.3 Manufacturing Process Analysis of Vaginal Yeast Infections Drug
10.4 Industry Chain Structure of Vaginal Yeast Infections Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaginal Yeast Infections Drug Distributors
11.3 Vaginal Yeast Infections Drug Customer
12 WORLD FORECAST REVIEW FOR VAGINAL YEAST INFECTIONS DRUG BY GEOGRAPHIC REGION
12.1 Global Vaginal Yeast Infections Drug Market Size Forecast by Region
12.1.1 Global Vaginal Yeast Infections Drug Forecast by Region (2027-2032)
12.1.2 Global Vaginal Yeast Infections Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Vaginal Yeast Infections Drug Forecast by Type (2027-2032)
12.7 Global Vaginal Yeast Infections Drug Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.1.3 Pfizer Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.2.3 Bayer Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.3.3 Sanofi Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Teva Pharmaceuticals
13.4.1 Teva Pharmaceuticals Company Information
13.4.2 Teva Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.4.3 Teva Pharmaceuticals Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Teva Pharmaceuticals Main Business Overview
13.4.5 Teva Pharmaceuticals Latest Developments
13.5 Sandoz
13.5.1 Sandoz Company Information
13.5.2 Sandoz Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.5.3 Sandoz Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sandoz Main Business Overview
13.5.5 Sandoz Latest Developments
13.6 Prestige Consumer Healthcare
13.6.1 Prestige Consumer Healthcare Company Information
13.6.2 Prestige Consumer Healthcare Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.6.3 Prestige Consumer Healthcare Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Prestige Consumer Healthcare Main Business Overview
13.6.5 Prestige Consumer Healthcare Latest Developments
13.7 Lupin Pharmaceuticals
13.7.1 Lupin Pharmaceuticals Company Information
13.7.2 Lupin Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.7.3 Lupin Pharmaceuticals Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Lupin Pharmaceuticals Main Business Overview
13.7.5 Lupin Pharmaceuticals Latest Developments
13.8 Bausch Health
13.8.1 Bausch Health Company Information
13.8.2 Bausch Health Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.8.3 Bausch Health Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bausch Health Main Business Overview
13.8.5 Bausch Health Latest Developments
13.9 Globela Pharma
13.9.1 Globela Pharma Company Information
13.9.2 Globela Pharma Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.9.3 Globela Pharma Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Globela Pharma Main Business Overview
13.9.5 Globela Pharma Latest Developments
13.10 Padagis
13.10.1 Padagis Company Information
13.10.2 Padagis Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.10.3 Padagis Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Padagis Main Business Overview
13.10.5 Padagis Latest Developments
13.11 Galderma
13.11.1 Galderma Company Information
13.11.2 Galderma Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.11.3 Galderma Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Galderma Main Business Overview
13.11.5 Galderma Latest Developments
13.12 Perrigo
13.12.1 Perrigo Company Information
13.12.2 Perrigo Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.12.3 Perrigo Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Perrigo Main Business Overview
13.12.5 Perrigo Latest Developments
13.13 Johnson & Johnson
13.13.1 Johnson & Johnson Company Information
13.13.2 Johnson & Johnson Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.13.3 Johnson & Johnson Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Johnson & Johnson Main Business Overview
13.13.5 Johnson & Johnson Latest Developments
13.14 Sinopharm Group
13.14.1 Sinopharm Group Company Information
13.14.2 Sinopharm Group Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.14.3 Sinopharm Group Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Sinopharm Group Main Business Overview
13.14.5 Sinopharm Group Latest Developments
13.15 Tongfang Pharmaceutical
13.15.1 Tongfang Pharmaceutical Company Information
13.15.2 Tongfang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.15.3 Tongfang Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Tongfang Pharmaceutical Main Business Overview
13.15.5 Tongfang Pharmaceutical Latest Developments
13.16 Lukang Pharmaceutical
13.16.1 Lukang Pharmaceutical Company Information
13.16.2 Lukang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.16.3 Lukang Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Lukang Pharmaceutical Main Business Overview
13.16.5 Lukang Pharmaceutical Latest Developments
13.17 Kelun Pharmaceutical
13.17.1 Kelun Pharmaceutical Company Information
13.17.2 Kelun Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.17.3 Kelun Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Kelun Pharmaceutical Main Business Overview
13.17.5 Kelun Pharmaceutical Latest Developments
13.18 Shijiazhuang Pharmaceutical Group
13.18.1 Shijiazhuang Pharmaceutical Group Company Information
13.18.2 Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.18.3 Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Shijiazhuang Pharmaceutical Group Main Business Overview
13.18.5 Shijiazhuang Pharmaceutical Group Latest Developments
13.19 Livzon Pharmaceutical
13.19.1 Livzon Pharmaceutical Company Information
13.19.2 Livzon Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.19.3 Livzon Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Livzon Pharmaceutical Main Business Overview
13.19.5 Livzon Pharmaceutical Latest Developments
13.20 Wuhan Haite Biopharmaceutical
13.20.1 Wuhan Haite Biopharmaceutical Company Information
13.20.2 Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.20.3 Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Wuhan Haite Biopharmaceutical Main Business Overview
13.20.5 Wuhan Haite Biopharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaginal Yeast Infections Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Vaginal Yeast Infections Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Vaginal Yeast Infections Drug by Country/Region, 2021, 2025 & 2032
2.2 Vaginal Yeast Infections Drug Segment by Type
2.2.1 Topical Drugs
2.2.2 Oral Drugs
2.2.3 Vaginal Yeast Infections Drug Sales by Type
2.2.3.1 Global Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
2.2.3.2 Global Vaginal Yeast Infections Drug Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Vaginal Yeast Infections Drug Sale Price by Type (2021-2026)
2.3 Vaginal Yeast Infections Drug Segment by Disease Type
2.3.1 Uncomplicated VVC
2.3.2 Complicated VVC
2.3.3 Other
2.3.4 Vaginal Yeast Infections Drug Sales by Disease Type
2.3.4.1 Global Vaginal Yeast Infections Drug Sales Market Share by Disease Type (2021-2026)
2.3.4.2 Global Vaginal Yeast Infections Drug Revenue and Market Share by Disease Type (2021-2026)
2.3.4.3 Global Vaginal Yeast Infections Drug Sale Price by Disease Type (2021-2026)
2.4 Vaginal Yeast Infections Drug Segment by Drug Class
2.4.1 Azoles
2.4.2 Polyenes
2.4.3 Novel Oral Antifungals
2.4.4 Other
2.4.5 Vaginal Yeast Infections Drug Sales by Drug Class
2.4.5.1 Global Vaginal Yeast Infections Drug Sales Market Share by Drug Class (2021-2026)
2.4.5.2 Global Vaginal Yeast Infections Drug Revenue and Market Share by Drug Class (2021-2026)
2.4.5.3 Global Vaginal Yeast Infections Drug Sale Price by Drug Class (2021-2026)
2.5 Vaginal Yeast Infections Drug Segment by Application
2.5.1 Hospital Pharmacies
2.5.2 Retail Pharmacies
2.5.3 Online
2.5.4 Vaginal Yeast Infections Drug Sales by Application
2.5.4.1 Global Vaginal Yeast Infections Drug Sale Market Share by Application (2021-2026)
2.5.4.2 Global Vaginal Yeast Infections Drug Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Vaginal Yeast Infections Drug Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Vaginal Yeast Infections Drug Breakdown Data by Company
3.1.1 Global Vaginal Yeast Infections Drug Annual Sales by Company (2021-2026)
3.1.2 Global Vaginal Yeast Infections Drug Sales Market Share by Company (2021-2026)
3.2 Global Vaginal Yeast Infections Drug Annual Revenue by Company (2021-2026)
3.2.1 Global Vaginal Yeast Infections Drug Revenue by Company (2021-2026)
3.2.2 Global Vaginal Yeast Infections Drug Revenue Market Share by Company (2021-2026)
3.3 Global Vaginal Yeast Infections Drug Sale Price by Company
3.4 Key Manufacturers Vaginal Yeast Infections Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaginal Yeast Infections Drug Product Location Distribution
3.4.2 Players Vaginal Yeast Infections Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VAGINAL YEAST INFECTIONS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Vaginal Yeast Infections Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global Vaginal Yeast Infections Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Vaginal Yeast Infections Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Vaginal Yeast Infections Drug Market Size by Country/Region (2021-2026)
4.2.1 Global Vaginal Yeast Infections Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global Vaginal Yeast Infections Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Vaginal Yeast Infections Drug Sales Growth
4.4 APAC Vaginal Yeast Infections Drug Sales Growth
4.5 Europe Vaginal Yeast Infections Drug Sales Growth
4.6 Middle East & Africa Vaginal Yeast Infections Drug Sales Growth
5 AMERICAS
5.1 Americas Vaginal Yeast Infections Drug Sales by Country
5.1.1 Americas Vaginal Yeast Infections Drug Sales by Country (2021-2026)
5.1.2 Americas Vaginal Yeast Infections Drug Revenue by Country (2021-2026)
5.2 Americas Vaginal Yeast Infections Drug Sales by Type (2021-2026)
5.3 Americas Vaginal Yeast Infections Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaginal Yeast Infections Drug Sales by Region
6.1.1 APAC Vaginal Yeast Infections Drug Sales by Region (2021-2026)
6.1.2 APAC Vaginal Yeast Infections Drug Revenue by Region (2021-2026)
6.2 APAC Vaginal Yeast Infections Drug Sales by Type (2021-2026)
6.3 APAC Vaginal Yeast Infections Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaginal Yeast Infections Drug by Country
7.1.1 Europe Vaginal Yeast Infections Drug Sales by Country (2021-2026)
7.1.2 Europe Vaginal Yeast Infections Drug Revenue by Country (2021-2026)
7.2 Europe Vaginal Yeast Infections Drug Sales by Type (2021-2026)
7.3 Europe Vaginal Yeast Infections Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaginal Yeast Infections Drug by Country
8.1.1 Middle East & Africa Vaginal Yeast Infections Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa Vaginal Yeast Infections Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa Vaginal Yeast Infections Drug Sales by Type (2021-2026)
8.3 Middle East & Africa Vaginal Yeast Infections Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaginal Yeast Infections Drug
10.3 Manufacturing Process Analysis of Vaginal Yeast Infections Drug
10.4 Industry Chain Structure of Vaginal Yeast Infections Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaginal Yeast Infections Drug Distributors
11.3 Vaginal Yeast Infections Drug Customer
12 WORLD FORECAST REVIEW FOR VAGINAL YEAST INFECTIONS DRUG BY GEOGRAPHIC REGION
12.1 Global Vaginal Yeast Infections Drug Market Size Forecast by Region
12.1.1 Global Vaginal Yeast Infections Drug Forecast by Region (2027-2032)
12.1.2 Global Vaginal Yeast Infections Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Vaginal Yeast Infections Drug Forecast by Type (2027-2032)
12.7 Global Vaginal Yeast Infections Drug Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.1.3 Pfizer Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.2.3 Bayer Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.3.3 Sanofi Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Teva Pharmaceuticals
13.4.1 Teva Pharmaceuticals Company Information
13.4.2 Teva Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.4.3 Teva Pharmaceuticals Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Teva Pharmaceuticals Main Business Overview
13.4.5 Teva Pharmaceuticals Latest Developments
13.5 Sandoz
13.5.1 Sandoz Company Information
13.5.2 Sandoz Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.5.3 Sandoz Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sandoz Main Business Overview
13.5.5 Sandoz Latest Developments
13.6 Prestige Consumer Healthcare
13.6.1 Prestige Consumer Healthcare Company Information
13.6.2 Prestige Consumer Healthcare Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.6.3 Prestige Consumer Healthcare Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Prestige Consumer Healthcare Main Business Overview
13.6.5 Prestige Consumer Healthcare Latest Developments
13.7 Lupin Pharmaceuticals
13.7.1 Lupin Pharmaceuticals Company Information
13.7.2 Lupin Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.7.3 Lupin Pharmaceuticals Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Lupin Pharmaceuticals Main Business Overview
13.7.5 Lupin Pharmaceuticals Latest Developments
13.8 Bausch Health
13.8.1 Bausch Health Company Information
13.8.2 Bausch Health Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.8.3 Bausch Health Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bausch Health Main Business Overview
13.8.5 Bausch Health Latest Developments
13.9 Globela Pharma
13.9.1 Globela Pharma Company Information
13.9.2 Globela Pharma Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.9.3 Globela Pharma Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Globela Pharma Main Business Overview
13.9.5 Globela Pharma Latest Developments
13.10 Padagis
13.10.1 Padagis Company Information
13.10.2 Padagis Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.10.3 Padagis Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Padagis Main Business Overview
13.10.5 Padagis Latest Developments
13.11 Galderma
13.11.1 Galderma Company Information
13.11.2 Galderma Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.11.3 Galderma Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Galderma Main Business Overview
13.11.5 Galderma Latest Developments
13.12 Perrigo
13.12.1 Perrigo Company Information
13.12.2 Perrigo Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.12.3 Perrigo Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Perrigo Main Business Overview
13.12.5 Perrigo Latest Developments
13.13 Johnson & Johnson
13.13.1 Johnson & Johnson Company Information
13.13.2 Johnson & Johnson Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.13.3 Johnson & Johnson Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Johnson & Johnson Main Business Overview
13.13.5 Johnson & Johnson Latest Developments
13.14 Sinopharm Group
13.14.1 Sinopharm Group Company Information
13.14.2 Sinopharm Group Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.14.3 Sinopharm Group Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Sinopharm Group Main Business Overview
13.14.5 Sinopharm Group Latest Developments
13.15 Tongfang Pharmaceutical
13.15.1 Tongfang Pharmaceutical Company Information
13.15.2 Tongfang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.15.3 Tongfang Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Tongfang Pharmaceutical Main Business Overview
13.15.5 Tongfang Pharmaceutical Latest Developments
13.16 Lukang Pharmaceutical
13.16.1 Lukang Pharmaceutical Company Information
13.16.2 Lukang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.16.3 Lukang Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Lukang Pharmaceutical Main Business Overview
13.16.5 Lukang Pharmaceutical Latest Developments
13.17 Kelun Pharmaceutical
13.17.1 Kelun Pharmaceutical Company Information
13.17.2 Kelun Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.17.3 Kelun Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Kelun Pharmaceutical Main Business Overview
13.17.5 Kelun Pharmaceutical Latest Developments
13.18 Shijiazhuang Pharmaceutical Group
13.18.1 Shijiazhuang Pharmaceutical Group Company Information
13.18.2 Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.18.3 Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Shijiazhuang Pharmaceutical Group Main Business Overview
13.18.5 Shijiazhuang Pharmaceutical Group Latest Developments
13.19 Livzon Pharmaceutical
13.19.1 Livzon Pharmaceutical Company Information
13.19.2 Livzon Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.19.3 Livzon Pharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Livzon Pharmaceutical Main Business Overview
13.19.5 Livzon Pharmaceutical Latest Developments
13.20 Wuhan Haite Biopharmaceutical
13.20.1 Wuhan Haite Biopharmaceutical Company Information
13.20.2 Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
13.20.3 Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Wuhan Haite Biopharmaceutical Main Business Overview
13.20.5 Wuhan Haite Biopharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Vaginal Yeast Infections Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Vaginal Yeast Infections Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Topical Drugs
Table 4. Major Players of Oral Drugs
Table 5. Global Vaginal Yeast Infections Drug Sales by Type (2021-2026) & (K Units)
Table 6. Global Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
Table 7. Global Vaginal Yeast Infections Drug Revenue by Type (2021-2026) & ($ million)
Table 8. Global Vaginal Yeast Infections Drug Revenue Market Share by Type (2021-2026)
Table 9. Global Vaginal Yeast Infections Drug Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Uncomplicated VVC
Table 11. Major Players of Complicated VVC
Table 12. Major Players of Other
Table 13. Global Vaginal Yeast Infections Drug Sales by Disease Type (2021-2026) & (K Units)
Table 14. Global Vaginal Yeast Infections Drug Sales Market Share by Disease Type (2021-2026)
Table 15. Global Vaginal Yeast Infections Drug Revenue by Disease Type (2021-2026) & ($ million)
Table 16. Global Vaginal Yeast Infections Drug Revenue Market Share by Disease Type (2021-2026)
Table 17. Global Vaginal Yeast Infections Drug Sale Price by Disease Type (2021-2026) & (US$/Unit)
Table 18. Major Players of Azoles
Table 19. Major Players of Polyenes
Table 20. Major Players of Novel Oral Antifungals
Table 21. Major Players of Other
Table 22. Global Vaginal Yeast Infections Drug Sales by Drug Class (2021-2026) & (K Units)
Table 23. Global Vaginal Yeast Infections Drug Sales Market Share by Drug Class (2021-2026)
Table 24. Global Vaginal Yeast Infections Drug Revenue by Drug Class (2021-2026) & ($ million)
Table 25. Global Vaginal Yeast Infections Drug Revenue Market Share by Drug Class (2021-2026)
Table 26. Global Vaginal Yeast Infections Drug Sale Price by Drug Class (2021-2026) & (US$/Unit)
Table 27. Global Vaginal Yeast Infections Drug Sale by Application (2021-2026) & (K Units)
Table 28. Global Vaginal Yeast Infections Drug Sale Market Share by Application (2021-2026)
Table 29. Global Vaginal Yeast Infections Drug Revenue by Application (2021-2026) & ($ million)
Table 30. Global Vaginal Yeast Infections Drug Revenue Market Share by Application (2021-2026)
Table 31. Global Vaginal Yeast Infections Drug Sale Price by Application (2021-2026) & (US$/Unit)
Table 32. Global Vaginal Yeast Infections Drug Sales by Company (2021-2026) & (K Units)
Table 33. Global Vaginal Yeast Infections Drug Sales Market Share by Company (2021-2026)
Table 34. Global Vaginal Yeast Infections Drug Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Vaginal Yeast Infections Drug Revenue Market Share by Company (2021-2026)
Table 36. Global Vaginal Yeast Infections Drug Sale Price by Company (2021-2026) & (US$/Unit)
Table 37. Key Manufacturers Vaginal Yeast Infections Drug Producing Area Distribution and Sales Area
Table 38. Players Vaginal Yeast Infections Drug Products Offered
Table 39. Vaginal Yeast Infections Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Vaginal Yeast Infections Drug Sales by Geographic Region (2021-2026) & (K Units)
Table 43. Global Vaginal Yeast Infections Drug Sales Market Share Geographic Region (2021-2026)
Table 44. Global Vaginal Yeast Infections Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Vaginal Yeast Infections Drug Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Vaginal Yeast Infections Drug Sales by Country/Region (2021-2026) & (K Units)
Table 47. Global Vaginal Yeast Infections Drug Sales Market Share by Country/Region (2021-2026)
Table 48. Global Vaginal Yeast Infections Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Vaginal Yeast Infections Drug Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Vaginal Yeast Infections Drug Sales by Country (2021-2026) & (K Units)
Table 51. Americas Vaginal Yeast Infections Drug Sales Market Share by Country (2021-2026)
Table 52. Americas Vaginal Yeast Infections Drug Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Vaginal Yeast Infections Drug Sales by Type (2021-2026) & (K Units)
Table 54. Americas Vaginal Yeast Infections Drug Sales by Application (2021-2026) & (K Units)
Table 55. APAC Vaginal Yeast Infections Drug Sales by Region (2021-2026) & (K Units)
Table 56. APAC Vaginal Yeast Infections Drug Sales Market Share by Region (2021-2026)
Table 57. APAC Vaginal Yeast Infections Drug Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Vaginal Yeast Infections Drug Sales by Type (2021-2026) & (K Units)
Table 59. APAC Vaginal Yeast Infections Drug Sales by Application (2021-2026) & (K Units)
Table 60. Europe Vaginal Yeast Infections Drug Sales by Country (2021-2026) & (K Units)
Table 61. Europe Vaginal Yeast Infections Drug Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Vaginal Yeast Infections Drug Sales by Type (2021-2026) & (K Units)
Table 63. Europe Vaginal Yeast Infections Drug Sales by Application (2021-2026) & (K Units)
Table 64. Middle East & Africa Vaginal Yeast Infections Drug Sales by Country (2021-2026) & (K Units)
Table 65. Middle East & Africa Vaginal Yeast Infections Drug Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Vaginal Yeast Infections Drug Sales by Type (2021-2026) & (K Units)
Table 67. Middle East & Africa Vaginal Yeast Infections Drug Sales by Application (2021-2026) & (K Units)
Table 68. Key Market Drivers & Growth Opportunities of Vaginal Yeast Infections Drug
Table 69. Key Market Challenges & Risks of Vaginal Yeast Infections Drug
Table 70. Key Industry Trends of Vaginal Yeast Infections Drug
Table 71. Vaginal Yeast Infections Drug Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Vaginal Yeast Infections Drug Distributors List
Table 74. Vaginal Yeast Infections Drug Customer List
Table 75. Global Vaginal Yeast Infections Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 76. Global Vaginal Yeast Infections Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Vaginal Yeast Infections Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 78. Americas Vaginal Yeast Infections Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Vaginal Yeast Infections Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 80. APAC Vaginal Yeast Infections Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Vaginal Yeast Infections Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Europe Vaginal Yeast Infections Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Vaginal Yeast Infections Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 84. Middle East & Africa Vaginal Yeast Infections Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Vaginal Yeast Infections Drug Sales Forecast by Type (2027-2032) & (K Units)
Table 86. Global Vaginal Yeast Infections Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global Vaginal Yeast Infections Drug Sales Forecast by Application (2027-2032) & (K Units)
Table 88. Global Vaginal Yeast Infections Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Pfizer Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Pfizer Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 91. Pfizer Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Pfizer Main Business
Table 93. Pfizer Latest Developments
Table 94. Bayer Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Bayer Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 96. Bayer Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Bayer Main Business
Table 98. Bayer Latest Developments
Table 99. Sanofi Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Sanofi Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 101. Sanofi Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Sanofi Main Business
Table 103. Sanofi Latest Developments
Table 104. Teva Pharmaceuticals Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Teva Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 106. Teva Pharmaceuticals Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Teva Pharmaceuticals Main Business
Table 108. Teva Pharmaceuticals Latest Developments
Table 109. Sandoz Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Sandoz Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 111. Sandoz Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Sandoz Main Business
Table 113. Sandoz Latest Developments
Table 114. Prestige Consumer Healthcare Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. Prestige Consumer Healthcare Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 116. Prestige Consumer Healthcare Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Prestige Consumer Healthcare Main Business
Table 118. Prestige Consumer Healthcare Latest Developments
Table 119. Lupin Pharmaceuticals Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. Lupin Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 121. Lupin Pharmaceuticals Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Lupin Pharmaceuticals Main Business
Table 123. Lupin Pharmaceuticals Latest Developments
Table 124. Bausch Health Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 125. Bausch Health Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 126. Bausch Health Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Bausch Health Main Business
Table 128. Bausch Health Latest Developments
Table 129. Globela Pharma Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 130. Globela Pharma Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 131. Globela Pharma Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Globela Pharma Main Business
Table 133. Globela Pharma Latest Developments
Table 134. Padagis Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 135. Padagis Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 136. Padagis Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Padagis Main Business
Table 138. Padagis Latest Developments
Table 139. Galderma Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 140. Galderma Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 141. Galderma Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Galderma Main Business
Table 143. Galderma Latest Developments
Table 144. Perrigo Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 145. Perrigo Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 146. Perrigo Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Perrigo Main Business
Table 148. Perrigo Latest Developments
Table 149. Johnson & Johnson Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 150. Johnson & Johnson Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 151. Johnson & Johnson Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Johnson & Johnson Main Business
Table 153. Johnson & Johnson Latest Developments
Table 154. Sinopharm Group Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 155. Sinopharm Group Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 156. Sinopharm Group Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Sinopharm Group Main Business
Table 158. Sinopharm Group Latest Developments
Table 159. Tongfang Pharmaceutical Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 160. Tongfang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 161. Tongfang Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. Tongfang Pharmaceutical Main Business
Table 163. Tongfang Pharmaceutical Latest Developments
Table 164. Lukang Pharmaceutical Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 165. Lukang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 166. Lukang Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Lukang Pharmaceutical Main Business
Table 168. Lukang Pharmaceutical Latest Developments
Table 169. Kelun Pharmaceutical Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 170. Kelun Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 171. Kelun Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. Kelun Pharmaceutical Main Business
Table 173. Kelun Pharmaceutical Latest Developments
Table 174. Shijiazhuang Pharmaceutical Group Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 175. Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 176. Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 177. Shijiazhuang Pharmaceutical Group Main Business
Table 178. Shijiazhuang Pharmaceutical Group Latest Developments
Table 179. Livzon Pharmaceutical Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 180. Livzon Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 181. Livzon Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 182. Livzon Pharmaceutical Main Business
Table 183. Livzon Pharmaceutical Latest Developments
Table 184. Wuhan Haite Biopharmaceutical Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 185. Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 186. Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 187. Wuhan Haite Biopharmaceutical Main Business
Table 188. Wuhan Haite Biopharmaceutical Latest Developments
Table 1. Vaginal Yeast Infections Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Vaginal Yeast Infections Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Topical Drugs
Table 4. Major Players of Oral Drugs
Table 5. Global Vaginal Yeast Infections Drug Sales by Type (2021-2026) & (K Units)
Table 6. Global Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
Table 7. Global Vaginal Yeast Infections Drug Revenue by Type (2021-2026) & ($ million)
Table 8. Global Vaginal Yeast Infections Drug Revenue Market Share by Type (2021-2026)
Table 9. Global Vaginal Yeast Infections Drug Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Uncomplicated VVC
Table 11. Major Players of Complicated VVC
Table 12. Major Players of Other
Table 13. Global Vaginal Yeast Infections Drug Sales by Disease Type (2021-2026) & (K Units)
Table 14. Global Vaginal Yeast Infections Drug Sales Market Share by Disease Type (2021-2026)
Table 15. Global Vaginal Yeast Infections Drug Revenue by Disease Type (2021-2026) & ($ million)
Table 16. Global Vaginal Yeast Infections Drug Revenue Market Share by Disease Type (2021-2026)
Table 17. Global Vaginal Yeast Infections Drug Sale Price by Disease Type (2021-2026) & (US$/Unit)
Table 18. Major Players of Azoles
Table 19. Major Players of Polyenes
Table 20. Major Players of Novel Oral Antifungals
Table 21. Major Players of Other
Table 22. Global Vaginal Yeast Infections Drug Sales by Drug Class (2021-2026) & (K Units)
Table 23. Global Vaginal Yeast Infections Drug Sales Market Share by Drug Class (2021-2026)
Table 24. Global Vaginal Yeast Infections Drug Revenue by Drug Class (2021-2026) & ($ million)
Table 25. Global Vaginal Yeast Infections Drug Revenue Market Share by Drug Class (2021-2026)
Table 26. Global Vaginal Yeast Infections Drug Sale Price by Drug Class (2021-2026) & (US$/Unit)
Table 27. Global Vaginal Yeast Infections Drug Sale by Application (2021-2026) & (K Units)
Table 28. Global Vaginal Yeast Infections Drug Sale Market Share by Application (2021-2026)
Table 29. Global Vaginal Yeast Infections Drug Revenue by Application (2021-2026) & ($ million)
Table 30. Global Vaginal Yeast Infections Drug Revenue Market Share by Application (2021-2026)
Table 31. Global Vaginal Yeast Infections Drug Sale Price by Application (2021-2026) & (US$/Unit)
Table 32. Global Vaginal Yeast Infections Drug Sales by Company (2021-2026) & (K Units)
Table 33. Global Vaginal Yeast Infections Drug Sales Market Share by Company (2021-2026)
Table 34. Global Vaginal Yeast Infections Drug Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Vaginal Yeast Infections Drug Revenue Market Share by Company (2021-2026)
Table 36. Global Vaginal Yeast Infections Drug Sale Price by Company (2021-2026) & (US$/Unit)
Table 37. Key Manufacturers Vaginal Yeast Infections Drug Producing Area Distribution and Sales Area
Table 38. Players Vaginal Yeast Infections Drug Products Offered
Table 39. Vaginal Yeast Infections Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Vaginal Yeast Infections Drug Sales by Geographic Region (2021-2026) & (K Units)
Table 43. Global Vaginal Yeast Infections Drug Sales Market Share Geographic Region (2021-2026)
Table 44. Global Vaginal Yeast Infections Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Vaginal Yeast Infections Drug Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Vaginal Yeast Infections Drug Sales by Country/Region (2021-2026) & (K Units)
Table 47. Global Vaginal Yeast Infections Drug Sales Market Share by Country/Region (2021-2026)
Table 48. Global Vaginal Yeast Infections Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Vaginal Yeast Infections Drug Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Vaginal Yeast Infections Drug Sales by Country (2021-2026) & (K Units)
Table 51. Americas Vaginal Yeast Infections Drug Sales Market Share by Country (2021-2026)
Table 52. Americas Vaginal Yeast Infections Drug Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Vaginal Yeast Infections Drug Sales by Type (2021-2026) & (K Units)
Table 54. Americas Vaginal Yeast Infections Drug Sales by Application (2021-2026) & (K Units)
Table 55. APAC Vaginal Yeast Infections Drug Sales by Region (2021-2026) & (K Units)
Table 56. APAC Vaginal Yeast Infections Drug Sales Market Share by Region (2021-2026)
Table 57. APAC Vaginal Yeast Infections Drug Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Vaginal Yeast Infections Drug Sales by Type (2021-2026) & (K Units)
Table 59. APAC Vaginal Yeast Infections Drug Sales by Application (2021-2026) & (K Units)
Table 60. Europe Vaginal Yeast Infections Drug Sales by Country (2021-2026) & (K Units)
Table 61. Europe Vaginal Yeast Infections Drug Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Vaginal Yeast Infections Drug Sales by Type (2021-2026) & (K Units)
Table 63. Europe Vaginal Yeast Infections Drug Sales by Application (2021-2026) & (K Units)
Table 64. Middle East & Africa Vaginal Yeast Infections Drug Sales by Country (2021-2026) & (K Units)
Table 65. Middle East & Africa Vaginal Yeast Infections Drug Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Vaginal Yeast Infections Drug Sales by Type (2021-2026) & (K Units)
Table 67. Middle East & Africa Vaginal Yeast Infections Drug Sales by Application (2021-2026) & (K Units)
Table 68. Key Market Drivers & Growth Opportunities of Vaginal Yeast Infections Drug
Table 69. Key Market Challenges & Risks of Vaginal Yeast Infections Drug
Table 70. Key Industry Trends of Vaginal Yeast Infections Drug
Table 71. Vaginal Yeast Infections Drug Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Vaginal Yeast Infections Drug Distributors List
Table 74. Vaginal Yeast Infections Drug Customer List
Table 75. Global Vaginal Yeast Infections Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 76. Global Vaginal Yeast Infections Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Vaginal Yeast Infections Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 78. Americas Vaginal Yeast Infections Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Vaginal Yeast Infections Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 80. APAC Vaginal Yeast Infections Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Vaginal Yeast Infections Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Europe Vaginal Yeast Infections Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Vaginal Yeast Infections Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 84. Middle East & Africa Vaginal Yeast Infections Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Vaginal Yeast Infections Drug Sales Forecast by Type (2027-2032) & (K Units)
Table 86. Global Vaginal Yeast Infections Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global Vaginal Yeast Infections Drug Sales Forecast by Application (2027-2032) & (K Units)
Table 88. Global Vaginal Yeast Infections Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Pfizer Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Pfizer Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 91. Pfizer Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Pfizer Main Business
Table 93. Pfizer Latest Developments
Table 94. Bayer Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Bayer Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 96. Bayer Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Bayer Main Business
Table 98. Bayer Latest Developments
Table 99. Sanofi Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Sanofi Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 101. Sanofi Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Sanofi Main Business
Table 103. Sanofi Latest Developments
Table 104. Teva Pharmaceuticals Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Teva Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 106. Teva Pharmaceuticals Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Teva Pharmaceuticals Main Business
Table 108. Teva Pharmaceuticals Latest Developments
Table 109. Sandoz Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Sandoz Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 111. Sandoz Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Sandoz Main Business
Table 113. Sandoz Latest Developments
Table 114. Prestige Consumer Healthcare Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. Prestige Consumer Healthcare Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 116. Prestige Consumer Healthcare Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Prestige Consumer Healthcare Main Business
Table 118. Prestige Consumer Healthcare Latest Developments
Table 119. Lupin Pharmaceuticals Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. Lupin Pharmaceuticals Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 121. Lupin Pharmaceuticals Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Lupin Pharmaceuticals Main Business
Table 123. Lupin Pharmaceuticals Latest Developments
Table 124. Bausch Health Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 125. Bausch Health Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 126. Bausch Health Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Bausch Health Main Business
Table 128. Bausch Health Latest Developments
Table 129. Globela Pharma Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 130. Globela Pharma Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 131. Globela Pharma Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Globela Pharma Main Business
Table 133. Globela Pharma Latest Developments
Table 134. Padagis Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 135. Padagis Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 136. Padagis Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Padagis Main Business
Table 138. Padagis Latest Developments
Table 139. Galderma Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 140. Galderma Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 141. Galderma Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Galderma Main Business
Table 143. Galderma Latest Developments
Table 144. Perrigo Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 145. Perrigo Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 146. Perrigo Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Perrigo Main Business
Table 148. Perrigo Latest Developments
Table 149. Johnson & Johnson Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 150. Johnson & Johnson Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 151. Johnson & Johnson Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Johnson & Johnson Main Business
Table 153. Johnson & Johnson Latest Developments
Table 154. Sinopharm Group Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 155. Sinopharm Group Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 156. Sinopharm Group Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Sinopharm Group Main Business
Table 158. Sinopharm Group Latest Developments
Table 159. Tongfang Pharmaceutical Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 160. Tongfang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 161. Tongfang Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. Tongfang Pharmaceutical Main Business
Table 163. Tongfang Pharmaceutical Latest Developments
Table 164. Lukang Pharmaceutical Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 165. Lukang Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 166. Lukang Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Lukang Pharmaceutical Main Business
Table 168. Lukang Pharmaceutical Latest Developments
Table 169. Kelun Pharmaceutical Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 170. Kelun Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 171. Kelun Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. Kelun Pharmaceutical Main Business
Table 173. Kelun Pharmaceutical Latest Developments
Table 174. Shijiazhuang Pharmaceutical Group Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 175. Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 176. Shijiazhuang Pharmaceutical Group Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 177. Shijiazhuang Pharmaceutical Group Main Business
Table 178. Shijiazhuang Pharmaceutical Group Latest Developments
Table 179. Livzon Pharmaceutical Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 180. Livzon Pharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 181. Livzon Pharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 182. Livzon Pharmaceutical Main Business
Table 183. Livzon Pharmaceutical Latest Developments
Table 184. Wuhan Haite Biopharmaceutical Basic Information, Vaginal Yeast Infections Drug Manufacturing Base, Sales Area and Its Competitors
Table 185. Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Product Portfolios and Specifications
Table 186. Wuhan Haite Biopharmaceutical Vaginal Yeast Infections Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 187. Wuhan Haite Biopharmaceutical Main Business
Table 188. Wuhan Haite Biopharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Vaginal Yeast Infections Drug
Figure 2. Vaginal Yeast Infections Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaginal Yeast Infections Drug Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Vaginal Yeast Infections Drug Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Vaginal Yeast Infections Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Vaginal Yeast Infections Drug Sales Market Share by Country/Region (2025)
Figure 10. Vaginal Yeast Infections Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Topical Drugs
Figure 12. Product Picture of Oral Drugs
Figure 13. Global Vaginal Yeast Infections Drug Sales Market Share by Type in 2026
Figure 14. Global Vaginal Yeast Infections Drug Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Uncomplicated VVC
Figure 16. Product Picture of Complicated VVC
Figure 17. Product Picture of Other
Figure 18. Global Vaginal Yeast Infections Drug Sales Market Share by Disease Type in 2026
Figure 19. Global Vaginal Yeast Infections Drug Revenue Market Share by Disease Type (2021-2026)
Figure 20. Product Picture of Azoles
Figure 21. Product Picture of Polyenes
Figure 22. Product Picture of Novel Oral Antifungals
Figure 23. Product Picture of Other
Figure 24. Global Vaginal Yeast Infections Drug Sales Market Share by Drug Class in 2026
Figure 25. Global Vaginal Yeast Infections Drug Revenue Market Share by Drug Class (2021-2026)
Figure 26. Vaginal Yeast Infections Drug Consumed in Hospital Pharmacies
Figure 27. Global Vaginal Yeast Infections Drug Market: Hospital Pharmacies (2021-2026) & (K Units)
Figure 28. Vaginal Yeast Infections Drug Consumed in Retail Pharmacies
Figure 29. Global Vaginal Yeast Infections Drug Market: Retail Pharmacies (2021-2026) & (K Units)
Figure 30. Vaginal Yeast Infections Drug Consumed in Online
Figure 31. Global Vaginal Yeast Infections Drug Market: Online (2021-2026) & (K Units)
Figure 32. Global Vaginal Yeast Infections Drug Sale Market Share by Application (2025)
Figure 33. Global Vaginal Yeast Infections Drug Revenue Market Share by Application in 2026
Figure 34. Vaginal Yeast Infections Drug Sales by Company in 2026 (K Units)
Figure 35. Global Vaginal Yeast Infections Drug Sales Market Share by Company in 2026
Figure 36. Vaginal Yeast Infections Drug Revenue by Company in 2026 ($ millions)
Figure 37. Global Vaginal Yeast Infections Drug Revenue Market Share by Company in 2026
Figure 38. Global Vaginal Yeast Infections Drug Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Vaginal Yeast Infections Drug Revenue Market Share by Geographic Region in 2026
Figure 40. Americas Vaginal Yeast Infections Drug Sales 2021-2026 (K Units)
Figure 41. Americas Vaginal Yeast Infections Drug Revenue 2021-2026 ($ millions)
Figure 42. APAC Vaginal Yeast Infections Drug Sales 2021-2026 (K Units)
Figure 43. APAC Vaginal Yeast Infections Drug Revenue 2021-2026 ($ millions)
Figure 44. Europe Vaginal Yeast Infections Drug Sales 2021-2026 (K Units)
Figure 45. Europe Vaginal Yeast Infections Drug Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Vaginal Yeast Infections Drug Sales 2021-2026 (K Units)
Figure 47. Middle East & Africa Vaginal Yeast Infections Drug Revenue 2021-2026 ($ millions)
Figure 48. Americas Vaginal Yeast Infections Drug Sales Market Share by Country in 2026
Figure 49. Americas Vaginal Yeast Infections Drug Revenue Market Share by Country (2021-2026)
Figure 50. Americas Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
Figure 51. Americas Vaginal Yeast Infections Drug Sales Market Share by Application (2021-2026)
Figure 52. United States Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Vaginal Yeast Infections Drug Sales Market Share by Region in 2026
Figure 57. APAC Vaginal Yeast Infections Drug Revenue Market Share by Region (2021-2026)
Figure 58. APAC Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
Figure 59. APAC Vaginal Yeast Infections Drug Sales Market Share by Application (2021-2026)
Figure 60. China Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 64. India Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Vaginal Yeast Infections Drug Sales Market Share by Country in 2026
Figure 68. Europe Vaginal Yeast Infections Drug Revenue Market Share by Country (2021-2026)
Figure 69. Europe Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
Figure 70. Europe Vaginal Yeast Infections Drug Sales Market Share by Application (2021-2026)
Figure 71. Germany Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 72. France Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Vaginal Yeast Infections Drug Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
Figure 78. Middle East & Africa Vaginal Yeast Infections Drug Sales Market Share by Application (2021-2026)
Figure 79. Egypt Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Vaginal Yeast Infections Drug in 2026
Figure 85. Manufacturing Process Analysis of Vaginal Yeast Infections Drug
Figure 86. Industry Chain Structure of Vaginal Yeast Infections Drug
Figure 87. Channels of Distribution
Figure 88. Global Vaginal Yeast Infections Drug Sales Market Forecast by Region (2027-2032)
Figure 89. Global Vaginal Yeast Infections Drug Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Vaginal Yeast Infections Drug Sales Market Share Forecast by Type (2027-2032)
Figure 91. Global Vaginal Yeast Infections Drug Revenue Market Share Forecast by Type (2027-2032)
Figure 92. Global Vaginal Yeast Infections Drug Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Vaginal Yeast Infections Drug Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Vaginal Yeast Infections Drug
Figure 2. Vaginal Yeast Infections Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaginal Yeast Infections Drug Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Vaginal Yeast Infections Drug Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Vaginal Yeast Infections Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Vaginal Yeast Infections Drug Sales Market Share by Country/Region (2025)
Figure 10. Vaginal Yeast Infections Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Topical Drugs
Figure 12. Product Picture of Oral Drugs
Figure 13. Global Vaginal Yeast Infections Drug Sales Market Share by Type in 2026
Figure 14. Global Vaginal Yeast Infections Drug Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Uncomplicated VVC
Figure 16. Product Picture of Complicated VVC
Figure 17. Product Picture of Other
Figure 18. Global Vaginal Yeast Infections Drug Sales Market Share by Disease Type in 2026
Figure 19. Global Vaginal Yeast Infections Drug Revenue Market Share by Disease Type (2021-2026)
Figure 20. Product Picture of Azoles
Figure 21. Product Picture of Polyenes
Figure 22. Product Picture of Novel Oral Antifungals
Figure 23. Product Picture of Other
Figure 24. Global Vaginal Yeast Infections Drug Sales Market Share by Drug Class in 2026
Figure 25. Global Vaginal Yeast Infections Drug Revenue Market Share by Drug Class (2021-2026)
Figure 26. Vaginal Yeast Infections Drug Consumed in Hospital Pharmacies
Figure 27. Global Vaginal Yeast Infections Drug Market: Hospital Pharmacies (2021-2026) & (K Units)
Figure 28. Vaginal Yeast Infections Drug Consumed in Retail Pharmacies
Figure 29. Global Vaginal Yeast Infections Drug Market: Retail Pharmacies (2021-2026) & (K Units)
Figure 30. Vaginal Yeast Infections Drug Consumed in Online
Figure 31. Global Vaginal Yeast Infections Drug Market: Online (2021-2026) & (K Units)
Figure 32. Global Vaginal Yeast Infections Drug Sale Market Share by Application (2025)
Figure 33. Global Vaginal Yeast Infections Drug Revenue Market Share by Application in 2026
Figure 34. Vaginal Yeast Infections Drug Sales by Company in 2026 (K Units)
Figure 35. Global Vaginal Yeast Infections Drug Sales Market Share by Company in 2026
Figure 36. Vaginal Yeast Infections Drug Revenue by Company in 2026 ($ millions)
Figure 37. Global Vaginal Yeast Infections Drug Revenue Market Share by Company in 2026
Figure 38. Global Vaginal Yeast Infections Drug Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Vaginal Yeast Infections Drug Revenue Market Share by Geographic Region in 2026
Figure 40. Americas Vaginal Yeast Infections Drug Sales 2021-2026 (K Units)
Figure 41. Americas Vaginal Yeast Infections Drug Revenue 2021-2026 ($ millions)
Figure 42. APAC Vaginal Yeast Infections Drug Sales 2021-2026 (K Units)
Figure 43. APAC Vaginal Yeast Infections Drug Revenue 2021-2026 ($ millions)
Figure 44. Europe Vaginal Yeast Infections Drug Sales 2021-2026 (K Units)
Figure 45. Europe Vaginal Yeast Infections Drug Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Vaginal Yeast Infections Drug Sales 2021-2026 (K Units)
Figure 47. Middle East & Africa Vaginal Yeast Infections Drug Revenue 2021-2026 ($ millions)
Figure 48. Americas Vaginal Yeast Infections Drug Sales Market Share by Country in 2026
Figure 49. Americas Vaginal Yeast Infections Drug Revenue Market Share by Country (2021-2026)
Figure 50. Americas Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
Figure 51. Americas Vaginal Yeast Infections Drug Sales Market Share by Application (2021-2026)
Figure 52. United States Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Vaginal Yeast Infections Drug Sales Market Share by Region in 2026
Figure 57. APAC Vaginal Yeast Infections Drug Revenue Market Share by Region (2021-2026)
Figure 58. APAC Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
Figure 59. APAC Vaginal Yeast Infections Drug Sales Market Share by Application (2021-2026)
Figure 60. China Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 64. India Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Vaginal Yeast Infections Drug Sales Market Share by Country in 2026
Figure 68. Europe Vaginal Yeast Infections Drug Revenue Market Share by Country (2021-2026)
Figure 69. Europe Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
Figure 70. Europe Vaginal Yeast Infections Drug Sales Market Share by Application (2021-2026)
Figure 71. Germany Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 72. France Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Vaginal Yeast Infections Drug Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Vaginal Yeast Infections Drug Sales Market Share by Type (2021-2026)
Figure 78. Middle East & Africa Vaginal Yeast Infections Drug Sales Market Share by Application (2021-2026)
Figure 79. Egypt Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Vaginal Yeast Infections Drug Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Vaginal Yeast Infections Drug in 2026
Figure 85. Manufacturing Process Analysis of Vaginal Yeast Infections Drug
Figure 86. Industry Chain Structure of Vaginal Yeast Infections Drug
Figure 87. Channels of Distribution
Figure 88. Global Vaginal Yeast Infections Drug Sales Market Forecast by Region (2027-2032)
Figure 89. Global Vaginal Yeast Infections Drug Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Vaginal Yeast Infections Drug Sales Market Share Forecast by Type (2027-2032)
Figure 91. Global Vaginal Yeast Infections Drug Revenue Market Share Forecast by Type (2027-2032)
Figure 92. Global Vaginal Yeast Infections Drug Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Vaginal Yeast Infections Drug Revenue Market Share Forecast by Application (2027-2032)
